Skip to main content
NASDAQ:SEEL

Seelos Therapeutics News Headlines

$5.19
+0.57 (+12.34 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.65
$5.24
50-Day Range
$4.26
$6.32
52-Week Range
$0.56
$6.60
Volume3.24 million shs
Average Volume7.87 million shs
Market Capitalization$407.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Headlines

Seelos Therapeutics (NASDAQ SEEL) News Headlines Today

SourceHeadline
Seelos Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare ConferenceSeelos Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 10 at 12:12 PM
Q2 2021 Earnings Estimate for Seelos Therapeutics, Inc. (NASDAQ:SEEL) Issued By B. RileyQ2 2021 Earnings Estimate for Seelos Therapeutics, Inc. (NASDAQ:SEEL) Issued By B. Riley
americanbankingnews.com - May 10 at 1:32 AM
Seelos Therapeutics, Inc. (NASDAQ:SEEL) Short Interest Up 84.5% in AprilSeelos Therapeutics, Inc. (NASDAQ:SEEL) Short Interest Up 84.5% in April
americanbankingnews.com - April 30 at 5:46 AM
-$0.09 EPS Expected for Seelos Therapeutics, Inc. (NASDAQ:SEEL) This Quarter-$0.09 EPS Expected for Seelos Therapeutics, Inc. (NASDAQ:SEEL) This Quarter
americanbankingnews.com - April 29 at 12:10 AM
Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - April 28 at 10:43 AM
Help May be On the Way for Patients with Parkinson’s DiseaseHelp May be On the Way for Patients with Parkinson’s Disease
baystreet.ca - April 20 at 9:34 AM
Seelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare ConferenceSeelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - April 19 at 8:53 AM
Heres Why Former Texas Gov. Rick Perry is Supportive of Psilocybin ResearchHere's Why Former Texas Gov. Rick Perry is Supportive of Psilocybin Research
marketwatch.com - April 16 at 7:55 PM
Here’s Why Former Texas Gov. Rick Perry is Supportive of Psilocybin ResearchHere’s Why Former Texas Gov. Rick Perry is Supportive of Psilocybin Research
baystreet.ca - April 16 at 2:28 PM
Seelos Therapeutics to Participate in the B. Riley Securities Neuroscience ConferenceSeelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference
finance.yahoo.com - April 15 at 1:35 PM
Mainstream Mental Health is Quickly Embracing Psychedelic Drug TherapiesMainstream Mental Health is Quickly Embracing Psychedelic Drug Therapies
baystreet.ca - April 12 at 12:57 PM
Seelos Therapeutics shares 6% higher as BTIG reiterates buy following Aptar dealSeelos Therapeutics shares 6% higher as BTIG reiterates buy following Aptar deal
seekingalpha.com - April 9 at 2:32 PM
Do Options Traders Know Something About Seelos (SEEL) Stock We Dont?Do Options Traders Know Something About Seelos (SEEL) Stock We Don't?
finance.yahoo.com - April 9 at 9:32 AM
Seelos Therapeutics Announces a Strategic Device Partnership With AptarGroup; Financial Terms Not DisclosedSeelos Therapeutics Announces a Strategic Device Partnership With AptarGroup; Financial Terms Not Disclosed
benzinga.com - April 7 at 10:16 AM
BRIEF-Seelos Therapeutics Announces Strategic Device Partnership With AptarGroup IncBRIEF-Seelos Therapeutics Announces Strategic Device Partnership With AptarGroup Inc
msn.com - April 6 at 7:27 AM
Seelos To Use Aptar Pharmas Bidose Liquid System Device With SLS-002 ProgramSeelos To Use Aptar Pharma's Bidose Liquid System Device With SLS-002 Program
markets.businessinsider.com - April 6 at 7:27 AM
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
finance.yahoo.com - April 6 at 7:27 AM
Why Seelos Therapeutics Stock Is Skyrocketing TodayWhy Seelos Therapeutics Stock Is Skyrocketing Today
finance.yahoo.com - March 20 at 5:03 AM
Midday Market Update: What Stocks Are Up Today?Midday Market Update: What Stocks Are Up Today?
finance.yahoo.com - March 20 at 5:03 AM
4 Hot Penny Stocks To Watch Before Next Week4 Hot Penny Stocks To Watch Before Next Week
marketwatch.com - March 12 at 4:57 PM
Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderSeelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
finance.yahoo.com - March 5 at 10:03 AM
With Psilocybin, Significant Progress is Being Made with Substance Use DisordersWith Psilocybin, Significant Progress is Being Made with Substance Use Disorders
marketwatch.com - March 2 at 5:21 PM
Seelos Therapeutics Buys Back Portion Of SLS002-Related RoyaltiesSeelos Therapeutics Buys Back Portion Of SLS002-Related Royalties
finance.yahoo.com - February 18 at 2:47 PM
Seelos Agrees To Repurchase Significant Portion Of Royalties Due On SLS-002Seelos Agrees To Repurchase Significant Portion Of Royalties Due On SLS-002
nasdaq.com - February 18 at 9:47 AM
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)
finance.yahoo.com - February 18 at 9:46 AM
Seelos Therapeutics to Participate in the 33rd Annual Roth ConferenceSeelos Therapeutics to Participate in the 33rd Annual Roth Conference
finance.yahoo.com - February 17 at 8:29 AM
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in AustraliaSeelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Australia
finance.yahoo.com - January 29 at 8:43 AM
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesSeelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
finance.yahoo.com - January 28 at 2:08 PM
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common StockSeelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
finance.yahoo.com - January 26 at 8:56 AM
Why Fluidigm, Seelos Therapeutics And More Are Moving TodayWhy Fluidigm, Seelos Therapeutics And More Are Moving Today
markets.businessinsider.com - January 22 at 2:12 PM
Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)
finance.yahoo.com - January 22 at 9:11 AM
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderSeelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
finance.yahoo.com - January 15 at 12:48 PM
Seelos Therapeutics Announces Year End 2020 Business UpdateSeelos Therapeutics Announces Year End 2020 Business Update
finance.yahoo.com - January 6 at 10:43 AM
SEEL.O - Seelos Therapeutics Inc Profile | ReutersSEEL.O - Seelos Therapeutics Inc Profile | Reuters
reuters.com - December 22 at 10:40 PM
Seelos Therapeutics IncSeelos Therapeutics Inc
reuters.com - December 21 at 8:18 PM
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in IsraelSeelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel
finance.yahoo.com - December 21 at 9:04 AM
Seelos Therapeutics Announces the Selection of SLS-005 (Trehalose) for the HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by the Harvard Medical SchoolSeelos Therapeutics Announces the Selection of SLS-005 (Trehalose) for the HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by the Harvard Medical School
finance.yahoo.com - December 15 at 12:47 PM
Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible NoteSeelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note
finance.yahoo.com - December 14 at 10:36 AM
Seelos Therapeutics Seeks Suicide Solution in KetamineSeelos Therapeutics Seeks Suicide Solution in Ketamine
finance.yahoo.com - December 11 at 1:52 PM
Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access EventSeelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event
finance.yahoo.com - December 8 at 5:48 PM
Seelos nabs US Orphan Drug status for SLS-005 in amyotrophic lateral sclerosisSeelos nabs US Orphan Drug status for SLS-005 in amyotrophic lateral sclerosis
seekingalpha.com - November 19 at 1:57 PM
Seelos Therapeutics Receives US Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral SclerosisSeelos Therapeutics Receives US Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis
finance.yahoo.com - November 19 at 1:57 PM
Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related DiseasesSeelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases
finance.yahoo.com - November 9 at 12:22 PM
Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007
finance.yahoo.com - October 26 at 1:44 PM
Seelos Therapeutics to Participate in Investor Conferences in NovemberSeelos Therapeutics to Participate in Investor Conferences in November
finance.yahoo.com - October 22 at 12:37 PM
Thinking about buying stock in Energous Corp, Seelos Therapeutics, Resonant Inc, American Airlines, or Norwegian Cruise Line?Thinking about buying stock in Energous Corp, Seelos Therapeutics, Resonant Inc, American Airlines, or Norwegian Cruise Line?
marketwatch.com - September 30 at 12:36 PM
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in ParkinsoSeelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinso
bloomberg.com - September 24 at 5:38 PM
Seelos Therapeutics inks deal with Duke University for SLS-004 in Parkinsons diseaseSeelos Therapeutics inks deal with Duke University for SLS-004 in Parkinson's disease
seekingalpha.com - September 23 at 9:57 AM
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's DiseaseSeelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease
finance.yahoo.com - September 23 at 9:57 AM
Seelos nabs new patent and notice of allowance in Japan for SLS-002Seelos nabs new patent and notice of allowance in Japan for SLS-002
seekingalpha.com - September 14 at 1:14 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.